CN111450008A - Whitening cream and preparation method thereof - Google Patents
Whitening cream and preparation method thereof Download PDFInfo
- Publication number
- CN111450008A CN111450008A CN202010362397.4A CN202010362397A CN111450008A CN 111450008 A CN111450008 A CN 111450008A CN 202010362397 A CN202010362397 A CN 202010362397A CN 111450008 A CN111450008 A CN 111450008A
- Authority
- CN
- China
- Prior art keywords
- whitening
- parts
- whitening cream
- water
- glabridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 193
- 239000006071 cream Substances 0.000 title claims abstract description 109
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 88
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 claims abstract description 66
- 229940093767 glabridin Drugs 0.000 claims abstract description 66
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 claims abstract description 66
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 claims abstract description 66
- PLISWQKGWPUZID-UHFFFAOYSA-N 2-hydroxy-4-methoxybenzoic acid;potassium Chemical compound [K].COC1=CC=C(C(O)=O)C(O)=C1 PLISWQKGWPUZID-UHFFFAOYSA-N 0.000 claims abstract description 58
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 57
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 53
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229940116229 borneol Drugs 0.000 claims abstract description 53
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 53
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 claims abstract description 49
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 claims abstract description 49
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 45
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 45
- 239000011570 nicotinamide Substances 0.000 claims abstract description 45
- -1 cyclohexane 1, 4-dicarboxylic acid ester Chemical class 0.000 claims abstract description 37
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 80
- 229940119217 chamomile extract Drugs 0.000 claims description 69
- 235000020221 chamomile extract Nutrition 0.000 claims description 69
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 54
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 46
- PXGZQGDTEZPERC-UHFFFAOYSA-L cyclohexane-1,4-dicarboxylate Chemical compound [O-]C(=O)C1CCC(C([O-])=O)CC1 PXGZQGDTEZPERC-UHFFFAOYSA-L 0.000 claims description 41
- 238000003756 stirring Methods 0.000 claims description 37
- 229920001577 copolymer Polymers 0.000 claims description 32
- 239000000686 essence Substances 0.000 claims description 29
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 28
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 27
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 27
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 27
- AMUTYVGRCVFCCD-UHFFFAOYSA-N 5,6-diaminopyridine-3-carboxylic acid Chemical compound NC1=CC(C(O)=O)=CN=C1N AMUTYVGRCVFCCD-UHFFFAOYSA-N 0.000 claims description 27
- 239000011703 D-panthenol Substances 0.000 claims description 27
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 27
- 235000004866 D-panthenol Nutrition 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 27
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 27
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 27
- 229940036350 bisabolol Drugs 0.000 claims description 27
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 27
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 27
- 229960003949 dexpanthenol Drugs 0.000 claims description 27
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 27
- 229930182478 glucoside Natural products 0.000 claims description 27
- 150000008131 glucosides Chemical class 0.000 claims description 27
- 229920002674 hyaluronan Polymers 0.000 claims description 27
- 229960003160 hyaluronic acid Drugs 0.000 claims description 27
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 27
- 229940057910 shea butter Drugs 0.000 claims description 27
- 239000000230 xanthan gum Substances 0.000 claims description 27
- 229920001285 xanthan gum Polymers 0.000 claims description 27
- 229940082509 xanthan gum Drugs 0.000 claims description 27
- 235000010493 xanthan gum Nutrition 0.000 claims description 27
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 26
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 26
- 229960000458 allantoin Drugs 0.000 claims description 26
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 26
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 26
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 25
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical group CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 24
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 24
- 239000011159 matrix material Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 238000010438 heat treatment Methods 0.000 claims description 21
- 238000001816 cooling Methods 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000003995 emulsifying agent Substances 0.000 claims description 13
- 239000002738 chelating agent Substances 0.000 claims description 12
- 239000002562 thickening agent Substances 0.000 claims description 12
- 239000003755 preservative agent Substances 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- 239000003623 enhancer Substances 0.000 claims description 9
- 239000004519 grease Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 claims description 7
- 229940104261 taurate Drugs 0.000 claims description 7
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 71
- 210000003491 skin Anatomy 0.000 abstract description 34
- 230000002401 inhibitory effect Effects 0.000 abstract description 18
- 210000000434 stratum corneum Anatomy 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 238000012546 transfer Methods 0.000 abstract description 5
- 230000004888 barrier function Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 239000000284 extract Substances 0.000 abstract description 2
- 241000628997 Flos Species 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 35
- 230000000052 comparative effect Effects 0.000 description 33
- 244000042664 Matricaria chamomilla Species 0.000 description 29
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 29
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 28
- 235000011187 glycerol Nutrition 0.000 description 26
- 229960001484 edetic acid Drugs 0.000 description 25
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 24
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 24
- 102000003425 Tyrosinase Human genes 0.000 description 24
- 108060008724 Tyrosinase Proteins 0.000 description 24
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 24
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 22
- 239000012071 phase Substances 0.000 description 22
- 239000004480 active ingredient Substances 0.000 description 20
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 20
- 239000000306 component Substances 0.000 description 19
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 18
- 239000002994 raw material Substances 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 238000005086 pumping Methods 0.000 description 15
- 239000010410 layer Substances 0.000 description 13
- 210000002780 melanosome Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 10
- 239000000787 lecithin Substances 0.000 description 10
- 235000010445 lecithin Nutrition 0.000 description 10
- 229940067606 lecithin Drugs 0.000 description 10
- 210000002752 melanocyte Anatomy 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 229960000271 arbutin Drugs 0.000 description 9
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 230000003020 moisturizing effect Effects 0.000 description 9
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 9
- 230000001603 reducing effect Effects 0.000 description 9
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- YFTGOBNOJKXZJC-UHFFFAOYSA-N 5,6-dihydroxyindole-2-carboxylic acid Chemical compound OC1=C(O)C=C2NC(C(=O)O)=CC2=C1 YFTGOBNOJKXZJC-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940020947 fluorescein sodium Drugs 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 6
- 108050009340 Endothelin Proteins 0.000 description 6
- 102000002045 Endothelin Human genes 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- MRIXVKKOHPQOFK-UHFFFAOYSA-N 4-methoxysalicylic acid Chemical compound COC1=CC=C(C(O)=O)C(O)=C1 MRIXVKKOHPQOFK-UHFFFAOYSA-N 0.000 description 5
- 206010040844 Skin exfoliation Diseases 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 108010051081 dopachrome isomerase Proteins 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- YRJKYHIIYRGTCC-UHFFFAOYSA-M potassium;2-hydroxy-4-methoxybenzoate Chemical compound [K+].COC1=CC=C(C([O-])=O)C(O)=C1 YRJKYHIIYRGTCC-UHFFFAOYSA-M 0.000 description 4
- 229960004889 salicylic acid Drugs 0.000 description 4
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 3
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 3
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000004299 exfoliation Methods 0.000 description 3
- 229940051250 hexylene glycol Drugs 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229940091250 magnesium supplement Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- IZZIWIAOVZOBLF-UHFFFAOYSA-N 5-methyloxysalicylic acid Natural products COC1=CC=C(O)C(C(O)=O)=C1 IZZIWIAOVZOBLF-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960002143 fluorescein Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- NGPNWUWGVIIIDG-LEJBHHMKSA-L magnesium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-yl] phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1OP([O-])([O-])=O NGPNWUWGVIIIDG-LEJBHHMKSA-L 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000000498 stratum granulosum Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XAWPKHNOFIWWNZ-UHFFFAOYSA-N 1h-indol-6-ol Chemical compound OC1=CC=C2C=CNC2=C1 XAWPKHNOFIWWNZ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- SGNZYJXNUURYCH-UHFFFAOYSA-N 5,6-dihydroxyindole Chemical compound C1=C(O)C(O)=CC2=C1NC=C2 SGNZYJXNUURYCH-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229930194248 Licoflavone Natural products 0.000 description 1
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 210000004430 acanthocyte Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108010020344 melanoproteins Proteins 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 210000000439 stratum lucidum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a whitening cream and a preparation method thereof, wherein the whitening cream comprises a whitening component, a penetration enhancer and a substrate; wherein the whitening component comprises flos Matricariae Chamomillae extract, glabridin, 4-methoxy potassium salicylate, nicotinamide and magnesium ascorbyl phosphate; the penetration enhancer includes hydrogenated lecithin, borneol and bis-diethoxydiol cyclohexane 1, 4-dicarboxylic acid ester. The whitening cream effectively changes the barrier function of the stratum corneum of the skin, thereby promoting the transdermal absorption of nutrient substances, reasonably collocating whitening components, inhibiting the generation and transfer of melanin, accelerating metabolism and improving the whitening effect.
Description
Technical Field
The invention relates to the technical field of daily chemicals, and particularly relates to whitening cream and a preparation method thereof.
Background
Whitening and freckle removing are all very concerned topics for people all the time. The oriental people hope to obtain white and smooth skin by using the whitening care product, and the European consumers mainly use the functional whitening cosmetic to reduce the deposition of pigment such as age pigment, chloasma and the like.
In recent years, new whitening agents for external use have been rapidly developed, and the most important action mechanism is to achieve whitening effects by inhibiting tyrosinase. Aiming at the action mechanism of tyrosinase, the method can be divided into the steps of inhibiting the activity of tyrosinase, reducing the generation and synthesis of tyrosinase, inhibiting the saccharification of tyrosinase and accelerating the decomposition of tyrosinase. In addition, some whitening agents may act on other links of melanin formation and on the transport metabolism of melanin. According to different action mechanisms, the currently developed whitening active ingredients mainly comprise: components for inhibiting tyrosinase activity, such as kojic acid and its derivatives, licoflavone, mulberry extract, etc.; ingredients that reduce tyrosinase production or synthesis, such as azelaic acid, placental peptide, plants of the Zingiberaceae family, and the like; inhibiting tyrosinase saccharification, so that tyrosinase can not be transferred from endoplasmic reticulum to melanosome, and active ingredients with the effect such as glucosamine, chondrosamine, and tunicin; ingredients for accelerating the decomposition of tyrosinase, such as linoleic acid and linolenic acid; components for reducing melanin and inhibiting melanin synthesis, such as vitamin C and its derivatives, arbutin, etc.; ingredients for inhibiting transfer of melanin granules to keratinocytes, such as niacinamide, green tea extract, soybean extract, and glycoprotein; ingredients that inhibit the binding of endothelin to melanocyte receptors, such as Matricaria chamomilla, and the like; ingredients that soften the stratum corneum and accelerate the exfoliation of the stratum corneum (accelerate the excretion of melanin out of the body), such as tartaric acid and the like. In addition, some components resisting ultraviolet rays are added into the whitening cosmetics to reduce the negative effects of ultraviolet rays, oxygen free radicals and the like on the physiological process of melanin formation.
At present, many whitening and skin-care products in the market have insignificant effects, and the main reasons are as follows: 1. the action mechanism of the ingredients of the product is single, and the single ingredient action path cannot achieve the best whitening effect due to the complex mechanism of melanin generation; 2. the problem of transdermal absorption is that although many tyrosinase inhibitors have obvious effects in vitro tests and are euphoric and mania, the tyrosinase inhibitors have little effect or very slow effect in many times and are frustrating when being practically applied to products, the important reason is the problem of transdermal absorption, and the epidermis is a cell overlapping layer with the thickness of 0.1-0.3 mm. From the surface to the basal layer, the stratum corneum, stratum granulosum, echinocyte and basal layer are divided. Melanocytes are mainly in the basal layer of epidermis, cosmetics are directly smeared on skin, tyrosinase inhibitors play a role, and the tyrosinase inhibitors have an effect on tyrosinase only by passing through the stratum corneum, the stratum lucidum, the stratum granulosum and the acanthocyte layer, reaching the melanocytes in the basal layer, passing through a melanocyte membrane and then passing through the melanosome membrane, so that the solution of the two problems has important significance for improving the skin whitening effect.
Disclosure of Invention
The first purpose of the invention is to provide a whitening cream aiming at the defects that the action mechanism of the product ingredients in the prior art is single and the obvious whitening effect cannot be achieved.
The second purpose of the invention is to provide a preparation method of the whitening cream.
The technical scheme adopted by the invention is as follows:
the invention provides a whitening cream, which comprises the following components in percentage by mass: 1.4-19.2% of whitening component, 1-3% of transdermal enhancer and 77.8-97.6% of matrix;
wherein the whitening component comprises chamomile extract, glabridin, 4-methoxy potassium salicylate, nicotinamide and magnesium ascorbyl phosphate;
the penetration enhancer comprises hydrogenated lecithin, borneol and bis-diethoxydiol cyclohexane 1, 4-dicarboxylic acid ester.
According to the whitening cream of the first aspect of the invention, the mass ratio of the chamomile extract to the glabridin to the 4-methoxysalicylic acid potassium to the nicotinamide to the magnesium ascorbyl phosphate is (1-10): (0.01-0.2): (0.05-2): (0.1-5): (0.05-2).
According to the whitening cream of the first aspect of the invention, the mass ratio of the chamomile extract to the glabridin to the 4-methoxysalicylic acid potassium to the nicotinamide to the magnesium ascorbyl phosphate is (5-8): (0.02-0.1): (0.05-2): (1-3): (0.1-1).
According to the whitening cream of the first aspect of the invention, the mass ratio of the chamomile extract to the glabridin to the 4-methoxysalicylic acid potassium to the nicotinamide to the magnesium ascorbyl phosphate is 6:0.03:1:2: 0.5.
According to the whitening cream of the first aspect of the invention, 100ml of chamomile extract contains active ingredients of more than or equal to 10g of chamomile raw materials.
According to the whitening cream of the first aspect of the invention, the mass ratio of the hydrogenated lecithin, the borneol and the bis-diethoxydiol cyclohexane 1, 4-dicarboxylate is (0.5-2): (0.02-0.6): (0.05-3).
According to the whitening cream of the first aspect of the invention, the mass ratio of the hydrogenated lecithin, the borneol and the bis-diethoxydiol cyclohexane 1, 4-dicarboxylate is (0.5-1.5): (0.05-0.2): (1-2).
According to the whitening cream of the first aspect of the invention, the mass ratio of the hydrogenated lecithin, the borneol and the bis-diethoxydiol cyclohexane 1, 4-dicarboxylate is 1:0.05: 1.5.
According to the whitening cream of the first aspect of the invention, the base contains grease, a thickening agent, an emulsifier, a preservative, a water-retaining agent, a chelating agent, essence and water.
According to the whitening cream of the first aspect of the invention, the matrix contains 1-20% of grease, 0.1-1% of thickening agent, 0.1-6% of emulsifier, 0.8-1.5% of preservative, 0-15% of water-retaining agent, 0-0.1% of chelating agent, 0-0.1% of essence and the balance of water, wherein the percentage is in percentage by mass of the whitening cream.
According to the whitening cream of the first aspect of the invention, the matrix contains 8-16% of grease, 0.3-0.8% of thickening agent, 2-5% of emulsifier, 0.8-1.5% of preservative, 0-15% of water-retaining agent, 0-0.1% of chelating agent, 0-0.1% of essence and the balance of water, wherein the percentage is in percentage by mass of the whitening cream.
According to the whitening cream of the first aspect of the invention, the oil is one or more of caprylic/capric triglyceride, isooctyl palmitate, shea butter, polydimethylsiloxane, bisabolol and tocopherol acetate.
According to the whitening cream of the first aspect of the invention, the content of isooctyl palmitate is less than or equal to 5%, preferably 3-5%; the content of the shea butter is less than or equal to 3 percent, preferably 0.5 to 2 percent; the content of the bisabolol is less than or equal to 1 percent, preferably 0.1-0.5 percent; the content of the polydimethylsiloxane is less than or equal to 3 percent, and preferably 1-3 percent; the content of the tocopherol acetate is less than or equal to 1%, preferably 0.5-1%, and the tocopherol acetate accounts for the mass percentage of the whitening and moisturizing cream.
According to the whitening cream of the first aspect of the invention, the thickener is one or more of xanthan gum and an ammonium acryloyldimethyl taurate/VP copolymer.
According to the whitening cream of the first aspect of the invention, the addition amount of the xanthan gum is less than or equal to 0.3 percent; the addition amount of the acryloyl dimethyl ammonium taurate/VP copolymer is less than or equal to 0.5 percent; the percentage is the mass percentage of the whitening cream.
The whitening cream according to the first aspect of the invention, wherein the emulsifier is 1618 alcohol and cetearyl glucoside.
The whitening cream according to the first aspect of the invention has the addition amount of the 1618 alcohol of 1-3%; the addition amount of the cetearyl glucoside is 2-5%; the percentage is the mass percentage of the whitening and moisturizing cream.
According to the whitening cream of the first aspect of the invention, the preservative is hexanediol and p-hydroxyacetophenone, and the mass ratio of the hexanediol to the p-hydroxyacetophenone is (0.3-1) to (0.3-1).
According to the whitening cream of the first aspect of the invention, the water-retaining agent is one or more of glycerin, butanediol, hyaluronic acid, allantoin, D-panthenol and lodestone; the content of the glycerol is less than or equal to 10.0 percent, and preferably 4-10 percent; the content of the butanediol is less than or equal to 10 percent, and the optimal content is 4-8 percent; the hyaluronic acid is less than or equal to 0.1 percent; the addition amount of the D-panthenol is less than or equal to 1 percent; the addition amount of the water-locking magnet is less than or equal to 0.8 percent; the percentage is the mass percentage of the whitening and moisturizing cream.
The whitening cream according to the first aspect of the invention, wherein the chelating agent is ethylenediaminetetraacetic acid.
The whitening cream according to the first aspect of the present invention, wherein the perfume is a perfume conventional in the art.
According to the whitening cream of the first aspect of the invention, the water is deionized water.
In a second aspect of the present invention, there is provided a method for preparing the whitening cream according to the first aspect of the present invention, comprising the steps of:
s1: uniformly mixing the thickening agent, the emulsifier, the water-retaining agent, the chelating agent and water, heating to 75-85 ℃, and preserving heat until the thickening agent, the emulsifier, the water-retaining agent, the chelating agent and the water are completely dissolved to obtain a mixture A; simultaneously heating the grease to 75-85 ℃, and completely dissolving to obtain an oil phase B;
s2: uniformly mixing the mixture A and the oil phase B, stirring in vacuum, and starting homogenizing to obtain a mixture C;
s3: and cooling the mixture C to 55-60 ℃, uniformly mixing the mixture C with whitening components, a penetration enhancer, a preservative and essence, and cooling to obtain the whitening cream.
According to the method for preparing whitening cream of the second aspect of the invention, the heating in step S1 is preferably performed under the condition of heating to 80 ℃. The mixing is preferably carried out in an aqueous phase pot, the heat preservation time is 5-15 min, preferably 10min, and the heat preservation aims to completely and uniformly disperse all the substances in the aqueous phase pot without particles.
According to the preparation method of the whitening cream in the second aspect of the invention, the homogenization in the step S2 is carried out for 5-10 min at 75-85 ℃, and the homogenization is preferably carried out in an emulsifying pot; the vacuum pressure is preferably-0.05 to-0.04 MPa, the method and the condition of the homogeneous emulsification are conventional in the field, and the temperature of the homogeneous emulsification is preferably 80 ℃; the time for the homogenisation emulsification is preferably 6 min.
According to the preparation method of the whitening cream of the second aspect of the invention, the cooling of step S3 is a conventional operation in the art, and is preferably to be cooled to 35-45 ℃, more preferably to be 40 ℃.
The invention has the beneficial effects that:
the penetration enhancer formed by compounding the hydrogenated lecithin, the borneol and the bis-diethoxydiol cyclo-1, 4-dicarboxylate in the whitening cream component effectively changes the barrier effect of a skin stratum corneum, is beneficial to increasing the transdermal speed or transdermal quantity of an effective component, improves the permeability of skin, and facilitates the penetration of nutrient substances, thereby promoting the transdermal absorption of the nutrient substances, and has excellent affinity, safety and no stimulation.
Drawings
Figure 1 is a transdermal permeability test of a permeation enhancer. Wherein Panel A is a graph of the transdermal permeation of 1% lecithin + fluorescein; panel B is a 0.05% borneol + fluorescein sodium percutaneous permeation map; FIG. C is a graph of the transdermal permeation of 1.5% bis-diethoxydiethylene glycol cyclohexane 1, 4-dicarboxylate + fluorescein sodium; and the diagram D is as follows: a percutaneous permeation profile of 0.05% borneol + 1.5% bis-diethoxydiol cyclohexane 1, 4-dicarboxylate + fluorescein sodium; panel E is a transdermal permeation profile of 0.05% borneol + 1% lecithin + 1.5% bis-diethoxydiol cyclohexane 1, 4-dicarboxylate + fluorescein sodium.
Fig. 2 is a whitening mechanism diagram.
Detailed Description
The present invention is further illustrated by the following examples, which are not to be construed as limiting the invention.
The whitening component and the transdermal enhancer in the invention have the following functions:
glabridin: the compound has the effects of inhibiting the activity of dopachrome tautomerase participating in melanin synthesis and inhibiting 5, 6-dihydroxyindole polymers, shows strong absorption to ultraviolet light and visible light due to the conjugation of the glabridin molecular structure, absorbs molecules of high-energy ultraviolet rays, transits from a ground state to an activated state, and then returns to the ground state from the activated state to release harmless low-energy rays.
Nicotinamide: can inhibit formation of melanin granules, effectively inhibit transfer of melanin to keratinocyte, promote cell desquamation of melanin-containing cells by accelerating renewal speed of skin cells, and improve skin from inside to outside, and whiten skin.
Plant extract chamomile extract (endothelin antagonist): can competitively inhibit the combination of endothelin and melanin cell membrane receptors, thereby achieving the purposes of inhibiting melanocyte proliferation and melanin generation caused by ultraviolet radiation, homogenizing skin color and achieving the whitening effect.
4-methoxy potassium salicylate (4 MSK): improve the abnormal function of cutin caused by ultraviolet irradiation, successfully discharge melanin and improve whitening effect.
VC phosphate ester magnesium: is vitamin C derivative, and is a water-soluble whitening agent. Not only has all the effects of vitamin C, but also overcomes the defects that vitamin C is not sensitive to light, heat, metal ions and the like and is easy to oxidize. VC phosphate magnesium inhibits tyrosinase activity, reduces melanin, has the effects of removing freckles and whitening skin, and can eliminate oxygen free radicals after entering a body, thereby having the functions of removing wrinkles and resisting aging. After being absorbed by skin, the magnesium can effectively resist ultraviolet ray invasion, can capture oxygen free radicals, promotes collagen generation, can effectively prevent and treat pigmentation, dispels various skin stains, can moisten, whiten and smooth the skin, is stable in VC magnesium phosphate, is non-toxic and non-irritant, and is an excellent additive of modern functional whitening cosmetics.
Hydrogenated lecithin: the lecithin is hydrogenated under the action of a catalyst to form a stable emulsifier, the active ingredient of the lecithin is well reserved, the lecithin, which is a component of cell membranes, is a component of the cell membranes, the function of the hydrogenated lecithin is almost the same as that of the phospholipid, the hydrogenated lecithin has very good affinity with the cell membranes, plays an important role in cell permeability and new generation, can maintain normal water balance of the skin, prevent desquamation, can reduce stimulation of a surfactant and reduce the allergy probability, and in addition, the lecithin has very good adaptability and permeability to the skin, can increase the skin softness, thicken the horny layer and is an essential ingredient for repairing the barrier function of the skin.
Borneol: can make the arrangement of lipid molecule orderly and increase its fluidity, improve the permeability of cell membrane, increase fluidity, and dilate subcutaneous capillary, and has solubilization effect on active substance, and further has effects of resisting bacteria, diminishing inflammation, and promoting wound healing.
Bis-diethoxydiethylene glycol cyclohexane 1, 4-dicarboxylate: is an amphiphilic substance, is soluble in water and oil, can promote the penetration of effective components to skin, improve the sticky feeling to skin, and has good moisture keeping effect.
Example 1
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening components comprise chamomile extract, glabridin, 4-methoxysalicylic acid potassium, nicotinamide and ascorbic acid magnesium phosphate, wherein the mass ratio of the chamomile extract to the glabridin to the 4-methoxysalicylic acid potassium to the nicotinamide to the ascorbic acid magnesium phosphate is 6:0.03:1:2: 0.5; the 100ml of chamomile extracting solution contains active ingredients of more than or equal to 10g of chamomile raw materials;
the transdermal enhancer comprises hydrogenated lecithin, borneol and bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, wherein the mass ratio of the hydrogenated lecithin to the borneol to the bis-diethoxydiol cyclohexane 1, 4-dicarboxylate is 1:0.05: 1.5.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediaminetetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of an ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 1 part of 4-methoxy potassium salicylate, 2 parts of nicotinamide, 0.5 part of magnesium ascorbyl phosphate, 0.03 part of glabridin, 0.05 part of borneol, 1.5 parts of bis-diethoxy diethylene glycol cyclohexane 1, 4-dicarboxylic acid ester, 6 parts of chamomile extracting solution, 0.5 part of magnetite, 0.5 part of D-panthenol, 0.55 part of hexanediol and 0.05 part of essence.
The preparation method of the whitening cream comprises the following steps:
s1: adding water into a water phase pot, starting a homogenizer to 400-600 rpm, adding an acryloyl dimethyl ammonium taurate/VP copolymer until the copolymer is dispersed and HAs no lump, stopping homogenizing, starting stirring at 30-40 rpm, adding ethylene diamine tetraacetic acid, glycerol, butanediol, trehalose, xanthan gum, cetearyl glucoside, allantoin, 4-methoxy potassium salicylate, HA hyaluronic acid and nicotinamide, heating to 80 ℃, keeping the temperature for 10min, and stirring to completely dissolve to obtain a mixture A; sequentially adding caprylic/capric triglyceride, isooctyl palmitate, shea butter, polydimethylsiloxane, 1618 alcohol, hydrogenated lecithin, bisabolol and tocopheryl acetate in an oil phase pot, heating to 80 ℃, and completely dissolving to obtain an oil phase B;
s2: heating the main pot to 80 ℃, starting vacuum, pumping a half of the mixture A into the main pot, starting stirring at 30-40 rpm, pumping the oil phase B into the main pot, finally pumping the rest mixture A into the main pot, keeping vacuum, reducing the stirring speed to 10-20 rpm, starting homogenizing for 6min, recovering stirring at 30-40 rpm after homogenizing is finished, and preserving heat for 10min to obtain a mixture C;
s3: slowly cooling, adding magnesium ascorbyl phosphate when the temperature of the system is reduced to 55-60 ℃, keeping the temperature and stirring the mixture to be uniform, continuously cooling, sequentially adding glabridin, borneol, bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, chamomile extract, lodestone, D-panthenol, hexanediol, p-hydroxyacetophenone and essence when the temperature of the system is reduced to below 45 ℃, stirring the mixture to be uniform, and cooling the mixture to 40 ℃ to obtain the whitening cream.
Example 2
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening components comprise chamomile extract, glabridin, 4-methoxysalicylic acid potassium, nicotinamide and ascorbic acid magnesium phosphate, wherein the mass ratio of the chamomile extract to the glabridin to the 4-methoxysalicylic acid potassium to the nicotinamide to the ascorbic acid magnesium phosphate is 10:0.01:0.05:1: 2; the 100ml of chamomile extracting solution contains active ingredients of more than or equal to 10g of chamomile raw materials;
the transdermal enhancer comprises hydrogenated lecithin, borneol and bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, and the mass ratio of the hydrogenated lecithin to the borneol to the bis-diethoxydiol cyclohexane 1, 4-dicarboxylate is 0.5:0.2: 1.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 0.5 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediaminetetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of an ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 0.05 part of 4-methoxy potassium salicylate, 1 part of nicotinamide, 2 parts of magnesium ascorbyl phosphate, 0.01 part of glabridin, 0.2 part of borneol, 1 part of bis-diethoxy diethylene glycol cyclohexane 1, 4-dicarboxylic acid ester, 10 parts of chamomile extracting solution, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexanediol and 0.05 part of essence.
The preparation method of the whitening cream comprises the following steps:
s1: adding water into a water phase pot, starting a homogenizer to 400-600 rpm, adding an acryloyl dimethyl ammonium taurate/VP copolymer until the copolymer is dispersed and HAs no lump, stopping homogenizing, starting stirring at 30-40 rpm, adding ethylene diamine tetraacetic acid, glycerol, butanediol, trehalose, xanthan gum, cetearyl glucoside, allantoin, 4-methoxy potassium salicylate, HA hyaluronic acid and nicotinamide, heating to 75-80 ℃, keeping the temperature for 5-10 min, and stirring to be completely dissolved to obtain a mixture A; sequentially adding caprylic/capric triglyceride, isooctyl palmitate, shea butter, polydimethylsiloxane, 1618 alcohol, hydrogenated lecithin, bisabolol and tocopheryl acetate in an oil phase pot, heating to 75-80 ℃, and completely dissolving to obtain an oil phase B;
s2: heating the main pot to 75-80 ℃, starting vacuum, pumping a half of the mixture A into the main pot, starting stirring at 30-40 rpm, pumping the oil phase B into the main pot, finally pumping the rest mixture A into the main pot, keeping vacuum, reducing the stirring speed to 10-20 rpm, starting homogenizing for 5-6 min, recovering stirring at 30-40 rpm after homogenizing is finished, and preserving heat for 5-10 min to obtain a mixture C;
s3: slowly cooling, adding magnesium ascorbyl phosphate when the temperature of the system is reduced to 55-60 ℃, keeping the temperature and stirring the mixture to be uniform, continuously cooling, sequentially adding glabridin, borneol, bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, chamomile extract, lodestone, D-panthenol, hexanediol, p-hydroxyacetophenone and essence when the temperature of the system is reduced to below 45 ℃, stirring the mixture to be uniform, and cooling the mixture to 35-40 ℃ to obtain the whitening cream.
Example 3
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening components comprise chamomile extract, glabridin, 4-methoxysalicylic acid potassium, nicotinamide and ascorbic acid magnesium phosphate, wherein the mass ratio of the chamomile extract to the glabridin to the 4-methoxysalicylic acid potassium to the nicotinamide to the ascorbic acid magnesium phosphate is 1:0.1:2:5: 1; the 100ml of chamomile extracting solution contains active ingredients of more than or equal to 10g of chamomile raw materials;
the transdermal enhancer comprises hydrogenated lecithin, borneol and bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, and the mass ratio of the hydrogenated lecithin to the borneol to the bis-diethoxydiol cyclohexane 1, 4-dicarboxylate is 1.5:0.6: 0.05.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1.5 parts of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediaminetetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of an ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 2 parts of 4-methoxy potassium salicylate, 5 parts of nicotinamide, 1 part of magnesium ascorbyl phosphate, 0.1 part of glabridin, 0.6 part of borneol, 0.05 part of bis-diethoxy diethylene glycol cyclohexane 1, 4-dicarboxylic acid ester, 1 part of chamomile extracting solution, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexanediol and 0.05 part of essence.
The preparation method of the whitening cream comprises the following steps:
s1: adding water into a water phase pot, starting a homogenizer to 400-600 rpm, adding an acryloyl dimethyl ammonium taurate/VP copolymer until the copolymer is dispersed and HAs no lump, stopping homogenizing, starting stirring at 30-40 rpm, adding ethylene diamine tetraacetic acid, glycerol, butanediol, trehalose, xanthan gum, cetearyl glucoside, allantoin, 4-methoxy potassium salicylate, HA hyaluronic acid and nicotinamide, heating to 80-85 ℃, keeping the temperature for 10-15 min, and stirring to be completely dissolved to obtain a mixture A; sequentially adding caprylic/capric triglyceride, isooctyl palmitate, shea butter, polydimethylsiloxane, 1618 alcohol, hydrogenated lecithin, bisabolol and tocopheryl acetate in an oil phase pot, heating to 80-85 ℃, and completely dissolving to obtain an oil phase B;
s2: heating the main pot to 80-85 ℃, starting vacuum, pumping a half of the mixture A into the main pot, starting stirring at 30-40 rpm, pumping the oil phase B into the main pot, finally pumping the rest mixture A into the main pot, keeping vacuum, reducing the stirring speed to 10-20 rpm, starting homogenizing for 6-10 min, recovering stirring at 30-40 rpm after homogenizing is finished, and preserving heat for 5-10 min to obtain a mixture C;
s3: slowly cooling, adding magnesium ascorbyl phosphate when the temperature of the system is reduced to 55-60 ℃, keeping the temperature and stirring the mixture to be uniform, continuously cooling, sequentially adding glabridin, borneol, bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, chamomile extract, lodestone, D-panthenol, hexanediol, p-hydroxyacetophenone and essence when the temperature of the system is reduced to below 45 ℃, stirring the mixture to be uniform, and cooling the mixture to 40-45 ℃ to obtain the whitening cream.
Example 4
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening components comprise chamomile extract, glabridin, 4-methoxysalicylic acid potassium, nicotinamide and ascorbic acid magnesium phosphate, wherein the mass ratio of the chamomile extract to the glabridin to the 4-methoxysalicylic acid potassium to the nicotinamide to the ascorbic acid magnesium phosphate is 5:0.2:2:3: 0.1; the 100ml of chamomile extracting solution contains active ingredients of more than or equal to 10g of chamomile raw materials;
the transdermal enhancer comprises hydrogenated lecithin, borneol and bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, and the mass ratio of the hydrogenated lecithin to the borneol to the bis-diethoxydiol cyclohexane 1, 4-dicarboxylate is 2:0.02: 2.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 2 parts of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediaminetetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of an ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 2 parts of 4-methoxy potassium salicylate, 3 parts of nicotinamide, 0.1 part of magnesium ascorbyl phosphate, 0.2 part of glabridin, 0.02 part of borneol, 2 parts of bis-diethoxy diethylene glycol cyclohexane 1, 4-dicarboxylic acid ester, 5 parts of chamomile extracting solution, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexanediol and 0.05 part of essence.
The preparation method of the whitening cream comprises the following steps:
s1: adding water into a water phase pot, starting a homogenizer to 400-600 rpm, adding an acryloyl dimethyl ammonium taurate/VP copolymer until the copolymer is dispersed and HAs no lump, stopping homogenizing, starting stirring at 30-40 rpm, adding ethylene diamine tetraacetic acid, glycerol, butanediol, trehalose, xanthan gum, cetearyl glucoside, allantoin, 4-methoxy potassium salicylate, HA hyaluronic acid and nicotinamide, heating to 75-80 ℃, keeping the temperature for 10-15 min, and stirring to be completely dissolved to obtain a mixture A; sequentially adding caprylic/capric triglyceride, isooctyl palmitate, shea butter, polydimethylsiloxane, 1618 alcohol, hydrogenated lecithin, bisabolol and tocopheryl acetate in an oil phase pot, heating to 75-80 ℃, and completely dissolving to obtain an oil phase B;
s2: heating the main pot to 75-80 ℃, starting vacuum, pumping a half of the mixture A into the main pot, starting stirring at 30-40 rpm, pumping the oil phase B into the main pot, finally pumping the rest mixture A into the main pot, keeping vacuum, reducing the stirring speed to 10-20 rpm, starting homogenizing for 6-10 min, recovering stirring at 30-40 rpm after homogenizing is finished, and preserving heat for 5-10 min to obtain a mixture C;
s3: slowly cooling, adding magnesium ascorbyl phosphate when the temperature of the system is reduced to 55-60 ℃, keeping the temperature and stirring the mixture to be uniform, continuously cooling, sequentially adding glabridin, borneol, bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, chamomile extract, lodestone, D-panthenol, hexanediol, p-hydroxyacetophenone and essence when the temperature of the system is reduced to below 45 ℃, stirring the mixture to be uniform, and cooling the mixture to 40-45 ℃ to obtain the whitening cream.
Example 5
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening components comprise chamomile extract, glabridin, 4-methoxysalicylic acid potassium, nicotinamide and ascorbic acid magnesium phosphate, wherein the mass ratio of the chamomile extract to the glabridin to the 4-methoxysalicylic acid potassium to the nicotinamide to the ascorbic acid magnesium phosphate is 8:0.02:0.05:0.1: 0.05; the 100ml of chamomile extracting solution contains active ingredients of more than or equal to 10g of chamomile raw materials;
the transdermal enhancer comprises hydrogenated lecithin, borneol and bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, wherein the mass ratio of the hydrogenated lecithin to the borneol to the bis-diethoxydiol cyclohexane 1, 4-dicarboxylate is 1:0.05: 3.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediaminetetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of an ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 0.05 part of 4-methoxy potassium salicylate, 0.1 part of nicotinamide, 0.05 part of magnesium ascorbyl phosphate, 0.02 part of glabridin, 0.05 part of borneol, 3 parts of bis-diethoxy diglycol cyclohexane 1, 4-dicarboxylate, 8 parts of chamomile extract, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexanediol and 0.05 part of essence.
The preparation method of the whitening cream comprises the following steps:
s1: adding water into a water phase pot, starting a homogenizer to 400-600 rpm, adding an acryloyl dimethyl ammonium taurate/VP copolymer until the copolymer is dispersed and HAs no lump, stopping homogenizing, starting stirring at 30-40 rpm, adding ethylene diamine tetraacetic acid, glycerol, butanediol, trehalose, xanthan gum, cetearyl glucoside, allantoin, 4-methoxy potassium salicylate, HA hyaluronic acid and nicotinamide, heating to 80-85 ℃, keeping the temperature for 10-15 min, and stirring to be completely dissolved to obtain a mixture A; sequentially adding caprylic/capric triglyceride, isooctyl palmitate, shea butter, polydimethylsiloxane, 1618 alcohol, hydrogenated lecithin, bisabolol and tocopheryl acetate in an oil phase pot, heating to 80-85 ℃, and completely dissolving to obtain an oil phase B;
s2: heating the main pot to 80-85 ℃, starting vacuum, pumping a half of the mixture A into the main pot, starting stirring at 30-40 rpm, pumping the oil phase B into the main pot, finally pumping the rest mixture A into the main pot, keeping vacuum, reducing the stirring speed to 10-20 rpm, starting homogenizing for 5-6 min, recovering stirring at 30-40 rpm after homogenizing is finished, and preserving heat for 5-10 min to obtain a mixture C;
s3: slowly cooling, adding magnesium ascorbyl phosphate when the temperature of the system is reduced to 55-60 ℃, keeping the temperature and stirring the mixture to be uniform, continuously cooling, sequentially adding glabridin, borneol, bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, chamomile extract, lodestone, D-panthenol, hexanediol, p-hydroxyacetophenone and essence when the temperature of the system is reduced to below 45 ℃, stirring the mixture to be uniform, and cooling the mixture to 35-40 ℃ to obtain the whitening cream.
Comparative example 1
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening component comprises glabridin, and the weight of the glabridin is 0.03 part.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediamine tetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 0.03 part of glabridin, 0.05 part of borneol, 1.5 parts of bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexanediol and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 2
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening components comprise chamomile extract, 4-methoxy potassium salicylate and nicotinamide, wherein the mass ratio of the chamomile extract to the 4-methoxy potassium salicylate to the nicotinamide is 6:1: 2; the 100ml of chamomile extract contains active ingredients of more than or equal to 10g of chamomile raw materials.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediamine tetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 1 part of 4-methoxypotassium salicylate, 2 parts of nicotinamide, 0.05 part of borneol, 1.5 parts of bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, 6 parts of chamomile extract, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexanediol, and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 3
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening component comprises chamomile extract, 4-methoxy potassium salicylate, nicotinamide and magnesium ascorbyl phosphate, and the mass ratio of the chamomile extract to the 4-methoxy potassium salicylate to the nicotinamide to the magnesium ascorbyl phosphate is 6:1:2: 0.5; the 100ml of chamomile extract contains active ingredients of more than or equal to 10g of chamomile raw materials.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediamine tetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 1 part of 4-methoxysalicylic acid potassium, 2 parts of nicotinamide, 0.5 part of magnesium ascorbyl phosphate, 0.05 part of borneol, 1.5 parts of bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, 6 parts of chamomile extract, 0.5 part of clavulan, 0.5 part of D-panthenol, 0.55 part of hexylene glycol, and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 4
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening components comprise chamomile extract, glabridin and 4-methoxy potassium salicylate, wherein the mass ratio of the chamomile extract to the glabridin to the 4-methoxy potassium salicylate is 6:0.03: 1; the 100ml of chamomile extract contains active ingredients of more than or equal to 10g of chamomile raw materials.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediamine tetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 1 part of 4-methoxysalicylic acid potassium, 0.03 part of glabridin, 0.05 part of borneol, 1.5 parts of bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, 6 parts of chamomile extract, 0.5 part of magnetite, 0.5 part of D-panthenol, 0.55 part of hexanediol and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 5
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening component comprises glabridin, nicotinamide and magnesium ascorbyl phosphate, and the mass ratio of the glabridin to the nicotinamide to the magnesium ascorbyl phosphate is 0.03:2: 0.5.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediamine tetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 2 parts of nicotinamide, 0.5 part of magnesium ascorbyl phosphate, 0.03 part of glabridin, 0.05 part of borneol, 1.5 parts of bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, 0.5 part of locked water, 0.5 part of magnetite, 0.5 part of D-panthenol, 0.55 part of hexanediol, and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 6
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening component comprises glabridin, 4-methoxysalicylic acid potassium, nicotinamide and ascorbic acid phosphate magnesium, wherein the mass ratio of the glabridin to the 4-methoxysalicylic acid potassium to the nicotinamide to the ascorbic acid phosphate magnesium is 0.03:1:2: 0.5.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediamine tetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 1 part of 4-methoxysalicylic acid potassium, 2 parts of nicotinamide, 0.5 part of magnesium ascorbyl phosphate, 0.03 part of glabridin, 0.05 part of borneol, 1.5 parts of bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexanediol and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 7
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening components comprise chamomile extract, glabridin, potassium 4-methoxysalicylate and magnesium ascorbyl phosphate, wherein the mass ratio of the chamomile extract to the glabridin to the potassium 4-methoxysalicylate to the magnesium ascorbyl phosphate is 6:0.03:1: 0.5; the 100ml of chamomile extract contains active ingredients of more than or equal to 10g of chamomile raw materials.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediamine tetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 1 part of 4-methoxypotassium salicylate, 0.5 part of magnesium ascorbyl phosphate, 0.03 part of glabridin, 0.05 part of borneol, 1.5 parts of bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, 6 parts of chamomile extract, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexanediol, and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 8
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening components comprise chamomile extract, glabridin, nicotinamide and magnesium ascorbyl phosphate, and the mass ratio of the chamomile extract to the glabridin to the nicotinamide to the magnesium ascorbyl phosphate is 6:0.03:2: 0.5; the 100ml of chamomile extract contains active ingredients of more than or equal to 10g of chamomile raw materials.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediamine tetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 2 parts of nicotinamide, 0.5 part of magnesium ascorbyl phosphate, 0.03 part of glabridin, 0.05 part of borneol, 1.5 parts of bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, 6 parts of chamomile extract, 0.5 part of clavulan, 0.5 part of D-panthenol, 0.55 part of hexylene glycol, and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 9
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening component comprises chamomile extract, glabridin, 4-methoxy potassium salicylate, nicotinamide and magnesium ascorbyl phosphate, wherein the mass ratio of the chamomile extract to the glabridin to the 4-methoxy potassium salicylate to the nicotinamide to the magnesium ascorbyl phosphate is 6:0.03:1:2:0.5, 1 part of hydrogenated lecithin, 0.05 part of borneol and 1.5 parts of bis-diethoxy diglycol cyclohexane 1, 4-dicarboxylic acid ester are not added; the 100ml of chamomile extract contains active ingredients of more than or equal to 10g of chamomile raw materials.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediamine tetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 1 part of 4-methoxysalicylic acid potassium, 2 parts of nicotinamide, 0.5 part of magnesium ascorbyl phosphate, 0.03 part of glabridin, 6 parts of chamomile extract, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexanediol and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 10
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening components comprise chamomile extract, glabridin, 4-methoxy potassium salicylate, nicotinamide and magnesium ascorbyl phosphate, wherein the mass ratio of the chamomile extract to the glabridin to the 4-methoxy potassium salicylate to the nicotinamide to the magnesium ascorbyl phosphate is 6:0.03:1:2:0.5, 1 part of hydrogenated lecithin and 0.05 part of borneol are not added; the 100ml of chamomile extract contains active ingredients of more than or equal to 10g of chamomile raw materials.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediamine tetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 1 part of 4-methoxysalicylate, 2 parts of nicotinamide, 0.5 part of magnesium ascorbyl phosphate, 0.03 part of glabridin, 1.5 parts of bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, 6 parts of chamomile extract, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexanediol, and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 11
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening component comprises chamomile extract, glabridin, 4-methoxy potassium salicylate, nicotinamide and magnesium ascorbyl phosphate, the mass ratio of the chamomile extract to the glabridin to the 4-methoxy potassium salicylate to the nicotinamide to the magnesium ascorbyl phosphate is 6:0.03:1:2:0.5, 1 part of hydrogenated lecithin and 1.5 parts of bis-diethoxy diethylene glycol cyclohexane 1, 4-dicarboxylic acid ester are not added; the 100ml of chamomile extract contains active ingredients of more than or equal to 10g of chamomile raw materials.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediamine tetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 1 part of 4-methoxysalicylic acid potassium, 2 parts of nicotinamide, 0.5 part of magnesium ascorbyl phosphate, 0.03 part of glabridin, 0.05 part of borneol, 6 parts of chamomile extract, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexanediol, and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 12
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening component comprises chamomile extract, glabridin, 4-methoxy potassium salicylate, nicotinamide and magnesium ascorbyl phosphate, wherein the mass ratio of the chamomile extract to the glabridin to the 4-methoxy potassium salicylate to the nicotinamide to the magnesium ascorbyl phosphate is 6:0.03:1:2:0.5, 0.05 part of borneol is not added, and 1.5 parts of bis-diethoxy diethylene glycol cyclohexane 1, 4-dicarboxylate is not added; the 100ml of chamomile extract contains active ingredients of more than or equal to 10g of chamomile raw materials.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediamine tetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 1 part of 4-methoxypotassium salicylate, 2 parts of nicotinamide, 0.5 part of magnesium ascorbyl phosphate, 0.03 part of glabridin, 6 parts of chamomile extract, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexanediol, and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 13
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening component comprises chamomile extract, arbutin, 4-methoxy potassium salicylate, nicotinamide and magnesium ascorbyl phosphate, and the mass ratio of the chamomile extract to the arbutin to the 4-methoxy potassium salicylate to the nicotinamide to the magnesium ascorbyl phosphate is 6:0.03:1:2: 0.5; the 100ml of chamomile extract contains active ingredients of more than or equal to 10g of chamomile raw materials.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediaminetetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of an ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 1 part of 4-methoxy potassium salicylate, 2 parts of nicotinamide, 0.5 part of magnesium ascorbyl phosphate, 0.03 part of arbutin, 0.05 part of borneol, 1.5 parts of bis-diethoxy diethylene glycol cyclohexane 1, 4-dicarboxylic acid ester, 6 parts of chamomile extracting solution, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexanediol and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 14
A whitening cream comprises whitening component, penetration enhancer and matrix. The whitening component comprises chamomile extract, arbutin, salicylic acid, nicotinamide and ascorbic acid, wherein the mass ratio of the chamomile extract to the arbutin to the salicylic acid to the nicotinamide to the ascorbic acid is 6:0.03:1:2: 0.5; the 100ml of chamomile extract contains active ingredients of more than or equal to 10g of chamomile raw materials.
The whitening cream comprises the following specific components in percentage by weight: 3 parts of caprylic/capric triglyceride, 3 parts of isooctyl palmitate, 1 part of shea butter, 2 parts of polydimethylsiloxane, 1.8 parts of 1618 alcohol, 3 parts of cetearyl glucoside, 1 part of hydrogenated lecithin, 0.3 part of bisabolol, 0.6 part of tocopheryl acetate, 0.05 part of ethylenediamine tetraacetic acid, 5 parts of glycerol, 7 parts of butanediol, 1 part of trehalose, 0.3 part of ammonium acryloyldimethyltaurate/VP copolymer, 0.2 part of xanthan gum, 0.2 part of allantoin, 0.55 part of p-hydroxyacetophenone, 0.05 part of HA hyaluronic acid, 1 part of salicylic acid, 2 parts of nicotinamide, 0.5 part of ascorbic acid, 0.03 part of arbutin, 0.05 part of borneol, 1.5 parts of bis-diethoxydiol cyclohexane 1, 4-dicarboxylate, 6 parts of chamomile extract, 0.5 part of lodestone, 0.5 part of D-panthenol, 0.55 part of hexylene glycol, and 0.05 part of essence.
The process steps are the same as in example 1.
Comparative example 15
Certain known whitening products are sold in the market.
Example 6 evaluation of whitening cream in clinical experiments
1. Selecting 90 female volunteers with the average age of 20-40 years, wherein the faces of the volunteers have spots caused by sun exposure, working pressure, age and the like, and the exclusion conditions of the test subjects accord with GB 171492 + 1997 'diagnosis standard and treatment principle of cosmetic contact dermatitis', the test subjects have no serious systemic diseases, no immunodeficiency or autoimmune diseases, no active allergic diseases, no allergic history to skin-care cosmetics, hormone medicines and immunosuppressants are not used for the whole body in 1 month, the test subjects are not used for pregnancy or lactation, no ethical contraindication exists, the test subjects are randomly divided into 18 groups, 5 of each group use the whitening creams prepared in the examples 1-5 and the comparative examples 1-13 respectively*Value, skin whiteness (brightness) (L)*Value):L*the values are white balance, and the larger the value, the more white the color is, and conversely, the color is biased to black, and the results are shown in table 1.
Table 1 whitening cream clinical trial evaluation L values statistical
The skin epidermis is sequentially provided with a horny layer, a transparent layer, a granular layer, an echinocyte layer and a basal layer from outside to inside, tyrosinase is positioned in a melanosome in melanocytes of the basal layer of the epidermis, and the melanosome is a special organelle of the melanocytes and is responsible for the generation of melanin. Melanin is a heterogeneous polyphenol-like polymer with a complex structure. In melanosomes, tyrosine is catalyzed by tyrosinase to produce dopa, dopa is dehydrogenated to form dopaquinone and rearranges into 5, 6 hydroxyindole (DHI), which is polymerized to combine with structural proteins in melanosomes to form melanoproteins, namely DHI melanin (melanin in the narrow sense), which is called eumelanin in combination with DHICA melanin.
In addition, PHEO melanin (pheomelanin), also known as depigmentation, is also present. The combination of eutmelanin and melatonin is called melanin (melanin in a broad sense), in which the formation of DHICA melanin is dependent on the activities of DHICA oxidase and dopachrome isomerase. In the metabolic pathway of DHICA melanin, dopachrome isomerase (TRP2) transfers dopachrome into a second metabolic pathway, the dopachrome is converted into 5, 6-dihydroxyindole carboxylic acid (5, 6-DHICA) under the action of dopachrome isomerase, and the DHICA is converted into DHICA melanin under the action of DHICA oxidase (TRPL). After the melanosome is mature, the melanosome is usually in the form of a composite corpuscle, two or three melanosomes are gathered together, a membrane is wrapped outside the composite corpuscle, the composite corpuscle is conveyed into keratin cells through branch processes, the melanosome is degraded by lysosomes, the melanosome is pushed outwards along with the differentiation of the keratin cells to the surface layer, and finally, the melanosome is removed after the keratin cells move to the surface.
From the clinical test data, it can be seen in table 1 that the skin color L value tends to increase and is significantly greater than the level before use after 2 weeks using the product of the present invention, and the value of example L after formulation is generally greater than that of comparative example, and the difference is statistically significant, indicating that the skin color gradually fades and the color of the mottle gradually fades after the whitening and moisturizing cream is applied to the face.
The results of example 1 and comparative examples 1 to 3 show that, in the course of various whitening pathways, the inhibition of tyrosinase activity by glabridin has a significant effect and a dominant effect on whitening, compared with several pathways of reducing synthesized melanin or inhibiting oxidation of dopa itself, inhibiting melanin transport, accelerating skin metabolism and exfoliation, and inhibiting endothelin activity, which is similar to some conclusions of related studies, because glabridin inhibits tyrosinase activity, inhibits both dopachrome interconversion and DHICA oxidase activity, and has an oxygen radical scavenging ability similar to SOD (superoxide dismutase).
The results of comparative example 2 and comparative example 3, and comparative example 4 and comparative example 7 show that magnesium ascorbyl phosphate promotes the whitening process, which is closely related to the melanin reducing effect of magnesium ascorbyl phosphate after entering into the body, and the related research also shows that magnesium can effectively resist ultraviolet invasion after being absorbed by skin, can capture oxygen free radicals, promote the generation of collagen, and can effectively prevent and treat pigmentation and remove various skin stains.
The embodiment 1 and the comparative example 7 show that the nicotinamide has obvious effect on inhibiting the transfer of melanin, can effectively block the ability of the melanin from entering cutin, and is possibly related to the compounding of the nicotinamide and the glabridin, and researches show that the activity of inhibiting tyrosinase is greatly improved after the nicotinamide and the glabridin are compounded.
Example 1 and comparative example 8 show that the lack of 4-methoxysalicylic acid greatly reduces the whitening effect, and it is known that when melanin is transferred to keratinocytes, if the deposited melanocytes cannot be metabolized and shed well, the skin will be dark and yellow, and the addition of 4-methoxysalicylic acid can obviously find that the potassium 4-methoxysalicylate has the effect of promoting whitening, which may be related to the salicylic acid structure contained in the potassium 4-methoxysalicylate to accelerate the skin metabolism and the cuticle shedding.
The results of the embodiment 1 and the comparative example 6 show that the whitening effect is obviously improved after the chamomile is compounded, and related researches show that when ultraviolet rays act on the skin and are stimulated by the outside, a large amount of endothelin is generated, tyrosinase is also activated to activate the formation process of melanin, and the chamomile extract can competitively inhibit the combination of the endothelin and a melanocyte membrane receptor, and inhibit the proliferation of melanocytes and the generation of melanin caused by ultraviolet radiation.
There is no significant difference in whitening effect between comparative example 6, comparative example 7 and comparative example 8, which indicates that in this complex system, the effects of inhibiting melanin transport by niacinamide, accelerating skin metabolism and cuticle exfoliation by 4-methoxysalicylic acid potassium and inhibiting the activity of endothelin are not very different, which may be related to the results of reduction of melanin produced due to tyrosinase inhibition by glabridin.
It can be seen from the above examples and comparative examples that whitening is a complex engineering system, and requires multiple ways to cooperate with each other to achieve a good whitening effect, and a single whitening way is difficult to combat skin problems caused by multiple factors and cannot achieve a good whitening effect. When hydrogenated lecithin, borneol and bis-diethoxydiol cyclohexane 1, 4-dicarboxylate are added to form the transdermal enhancer, the permeation of whitening components is promoted, and the whitening effect is improved, wherein the experimental results are shown in example 1 and comparative examples 9-12.
In examples 1-5, example 1 has the best effect, exerts the effect higher than that of a certain known whitening product, and uses whitening components with similar effects such as arbutin, salicylic acid and ascorbic acid to replace glabridin, 4-methoxy potassium salicylate and magnesium ascorbyl phosphate respectively, and the experimental results are shown in comparative examples 13 and 14, but the whitening effect is not obvious compared with example 1, and probably because arbutin and ascorbic acid are easy to oxidize in an aqueous solution and have poor stability in the product, namely poor stability such as heat resistance and light resistance, and the whitening effect cannot be completely exerted.
2. The moisture content of the skin is measured by a moisture meter CM825, the moisture content of the skin is recorded and measured on the 0 th day and the 28 th day, and the moisturizing effect of the whitening cream is evaluated, and the results are shown in the table 2:
TABLE 2 statistics of moisturizing effect of whitening cream
The experimental results in table 2 show that the moisture content of the skin can be significantly increased in comparative example 9, example 1 and comparative example 15, which indicates that the product has a good moisturizing function, the moisture content of the skin is increased to more than 30% after 28 days of continuous use, the moisturizing capability of the product is improved after the accelerator is added, and the accelerator can promote the whitening and the penetration of moisturizing components, so that the water-locking capability is improved.
Example 7 transdermal Permeability test
Grouping of sample experiments: a: 1% lecithin + fluorescein; b: 0.05% borneol and fluorescein sodium; c: 1.5% bis-diethoxydiethylene glycol cyclohexane 1, 4-dicarboxylate + fluorescein sodium; d: 0.05% of borneol, 1.5% of bis-diethoxydiol cyclohexane 1, 4-dicarboxylate and sodium fluorescein; e: 0.05% of borneol, 1% of lecithin, 1.5% of bis-diethoxydiol cyclohexane 1, 4-dicarboxylate and sodium fluorescein.
The sample was introduced into a Franz diffusion cell using a three-dimensional epidermis model L abCyte (J-Tec Co.), 10ppm of sodium fluorescein was added thereto and exposed for 4 hours, and then the epidermis model was washed 10 times with PBS and frozen sections were prepared after washing and observed with a fluorescence microscope, and the results are shown in FIG. 1.
Experimental results show that when 0.05% of borneol, 1% of lecithin and 1.5% of bis-diethoxydiol cyclohexane 1, 4-dicarboxylate are compounded, the introduction effect of fluorescein sodium can be greatly improved, and that the compounding of the lecithin, the borneol and the bis-diethoxydiol cyclohexane 1, 4-dicarboxylate can effectively change the barrier effect of the stratum corneum of the skin, improve the permeability of the skin and contribute to the increase of the transdermal speed or the transdermal quantity of the effective components.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention.
Claims (10)
1. The whitening cream comprises the following components in percentage by mass: 1.4-19.2% of whitening component, 1-3% of transdermal enhancer and 77.8-97.6% of matrix;
wherein the whitening component comprises chamomile extract, glabridin, 4-methoxy potassium salicylate, nicotinamide and magnesium ascorbyl phosphate;
the penetration enhancer comprises hydrogenated lecithin, borneol and bis-diethoxydiol cyclohexane 1, 4-dicarboxylic acid ester.
2. The whitening cream according to claim 1, wherein the mass ratio of the chamomile extract to the glabridin to the 4-methoxysalicylic acid potassium to the nicotinamide to the magnesium ascorbyl phosphate is (1-10): 0.01-0.2): 0.05-2): 0.1-5): 0.05-2.
3. The whitening cream according to claim 2, wherein the mass ratio of the chamomile extract to the glabridin to the 4-methoxysalicylic acid potassium to the nicotinamide to the magnesium ascorbyl phosphate is 6:0.03:1:2: 0.5.
4. The whitening cream according to claim 1, wherein the mass ratio of the hydrogenated lecithin, the borneol and the bis-diethoxydiol cyclohexane 1, 4-dicarboxylate is (0.5-2): (0.02-0.6): (0.05-3).
5. The whitening cream according to claim 4, wherein the mass ratio of the hydrogenated lecithin to the borneol to the bis-diethoxydiol cyclohexane-1, 4-dicarboxylate is 1:0.05: 1.5.
6. The whitening cream according to claim 1, wherein the base comprises grease, a thickening agent, an emulsifier, a preservative, a water-retaining agent, a chelating agent, essence and water.
7. The whitening cream as claimed in claim 6, characterized in that the base comprises 1-20% of grease, 0.1-1% of thickening agent, 0.1-6% of emulsifier, 0.8-1.5% of preservative, 0-15% of water-retaining agent, 0-0.1% of chelating agent, 0-0.1% of essence and the balance of water, wherein the percentage is the mass percentage of the whitening cream.
8. The whitening cream according to claim 7, characterized in that the base comprises 8-16% of grease, 0.3-0.8% of thickening agent, 2-5% of emulsifier, 0.8-1.5% of preservative, 0-15% of water-retaining agent, 0-0.1% of chelating agent, 0-0.1% of essence and the balance of water, wherein the percentage is the mass percentage of the whitening cream.
9. The whitening cream of claims 6 to 8, wherein the oil is one or more of caprylic capric triglyceride, isooctyl palmitate, shea butter, polydimethylsiloxane, bisabolol and tocopheryl acetate; the thickening agent is one or more of xanthan gum and acryloyl dimethyl ammonium taurate/VP copolymer; the emulsifier is 1618 alcohol and cetearyl glucoside; the preservative is hexanediol and p-hydroxyacetophenone; the water-retaining agent is one or more of glycerol, butanediol, hyaluronic acid, allantoin, D-panthenol and lodestone; the chelating agent is ethylenediamine tetraacetic acid.
10. A process for the preparation of a whitening cream as claimed in any of claims 6 to 9, comprising the steps of:
s1: uniformly mixing the thickening agent, the emulsifier, the water-retaining agent, the chelating agent and water, heating to 75-85 ℃, and preserving heat until the thickening agent, the emulsifier, the water-retaining agent, the chelating agent and the water are completely dissolved to obtain a mixture A; simultaneously heating the grease to 75-85 ℃, and completely dissolving to obtain an oil phase B;
s2: uniformly mixing the mixture A and the oil phase B, stirring in vacuum, and starting homogenizing to obtain a mixture C;
s3: and cooling the mixture C to 55-60 ℃, uniformly mixing the mixture C with whitening components, a penetration enhancer, a preservative and essence, and cooling to obtain the whitening cream.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010362397.4A CN111450008A (en) | 2020-04-30 | 2020-04-30 | Whitening cream and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010362397.4A CN111450008A (en) | 2020-04-30 | 2020-04-30 | Whitening cream and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111450008A true CN111450008A (en) | 2020-07-28 |
Family
ID=71670584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010362397.4A Pending CN111450008A (en) | 2020-04-30 | 2020-04-30 | Whitening cream and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111450008A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112120988A (en) * | 2020-11-06 | 2020-12-25 | 广州市科能化妆品科研有限公司 | Whitening sunscreen lotion and preparation method thereof |
| CN112587456A (en) * | 2020-12-25 | 2021-04-02 | 上海林清轩生物科技有限公司 | Repairing and whitening composition and preparation method thereof |
| CN113425663A (en) * | 2021-08-18 | 2021-09-24 | 皖西学院 | Preparation method of dendrobium flower soybean skin-beautifying mask |
| CN113975215A (en) * | 2021-11-18 | 2022-01-28 | 广州梵之容化妆品有限公司 | Whitening cream and preparation method thereof |
| WO2022210146A1 (en) * | 2021-04-02 | 2022-10-06 | 株式会社 資生堂 | Cosmetic preparation |
| CN115990118A (en) * | 2022-12-29 | 2023-04-21 | 广州梵之容化妆品有限公司 | High-transdermal water-permeability-promoting soluble glabridin composition and preparation method thereof |
| WO2024090247A1 (en) * | 2022-10-28 | 2024-05-02 | 株式会社 資生堂 | Beauty composition, beauty method, and agent for promoting skin permeability of alkoxy salicylic acid or salt thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103340785A (en) * | 2013-07-05 | 2013-10-09 | 上海珍馨化工科技有限公司 | Chamomile toning lotion |
| CN104188887A (en) * | 2014-09-29 | 2014-12-10 | 广东真丽斯化妆品有限公司 | Whitening composition and application thereof |
| CN105411912A (en) * | 2015-11-30 | 2016-03-23 | 青岛盛嘉信息科技有限公司 | Skin-whitening cosmetic containing juicy peach powder, chamomile extract and licorice extract |
| CN106309272A (en) * | 2016-08-24 | 2017-01-11 | 广东芭薇生物科技股份有限公司 | Whitening cream and preparing method thereof |
| CN109172430A (en) * | 2018-11-01 | 2019-01-11 | 广东芭薇生物科技股份有限公司 | A kind of rush penetrative composition containing small-micelle water and its application in cosmetics |
-
2020
- 2020-04-30 CN CN202010362397.4A patent/CN111450008A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103340785A (en) * | 2013-07-05 | 2013-10-09 | 上海珍馨化工科技有限公司 | Chamomile toning lotion |
| CN104188887A (en) * | 2014-09-29 | 2014-12-10 | 广东真丽斯化妆品有限公司 | Whitening composition and application thereof |
| CN105411912A (en) * | 2015-11-30 | 2016-03-23 | 青岛盛嘉信息科技有限公司 | Skin-whitening cosmetic containing juicy peach powder, chamomile extract and licorice extract |
| CN106309272A (en) * | 2016-08-24 | 2017-01-11 | 广东芭薇生物科技股份有限公司 | Whitening cream and preparing method thereof |
| CN109172430A (en) * | 2018-11-01 | 2019-01-11 | 广东芭薇生物科技股份有限公司 | A kind of rush penetrative composition containing small-micelle water and its application in cosmetics |
Non-Patent Citations (2)
| Title |
|---|
| 万禁禁等: "一种美白霜的研制及其美白功效评价", 《日用化学工业》 * |
| 汪多仁编著: "《绿色日用化学品》", 30 April 2007, 科学技术出版社 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112120988A (en) * | 2020-11-06 | 2020-12-25 | 广州市科能化妆品科研有限公司 | Whitening sunscreen lotion and preparation method thereof |
| CN112587456A (en) * | 2020-12-25 | 2021-04-02 | 上海林清轩生物科技有限公司 | Repairing and whitening composition and preparation method thereof |
| WO2022210146A1 (en) * | 2021-04-02 | 2022-10-06 | 株式会社 資生堂 | Cosmetic preparation |
| CN113425663A (en) * | 2021-08-18 | 2021-09-24 | 皖西学院 | Preparation method of dendrobium flower soybean skin-beautifying mask |
| CN113975215A (en) * | 2021-11-18 | 2022-01-28 | 广州梵之容化妆品有限公司 | Whitening cream and preparation method thereof |
| WO2024090247A1 (en) * | 2022-10-28 | 2024-05-02 | 株式会社 資生堂 | Beauty composition, beauty method, and agent for promoting skin permeability of alkoxy salicylic acid or salt thereof |
| CN115990118A (en) * | 2022-12-29 | 2023-04-21 | 广州梵之容化妆品有限公司 | High-transdermal water-permeability-promoting soluble glabridin composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111450008A (en) | Whitening cream and preparation method thereof | |
| CN108451837B (en) | Whitening liquid crystal composition and preparation method and application thereof | |
| CA2749750C (en) | Skin care compositions and methods of use thereof | |
| US20110229538A1 (en) | Topical skin care composition | |
| US20080214669A1 (en) | Composition and Method For Treating Hyperpigmented Skin | |
| CN107374988B (en) | Preparation method of nonionic vesicle with whitening effect | |
| KR20140024840A (en) | Exopolysaccharide for the treatment and/or care of the skin, mucous membranes, hair and/or nails | |
| CN104856892A (en) | Cosmetic or skin care product preparation rich in growth factors and preparation method therefor | |
| KR20100136537A (en) | Cosmetic compositions comprising exopolysaccharides derived from microbial mats, and use thereof | |
| CN106309154A (en) | Skin care substrate with long acting moisturizing and whitening effects and preparation and application of skin care substrate | |
| CN104983647A (en) | Deep restoration mask and making method thereof | |
| CN104983666A (en) | Repair and regeneration mask product and preparation method thereof | |
| CN111514058A (en) | Skin whitening and brightening agent and preparation method thereof | |
| JP2008260721A (en) | External preparation for skin | |
| CN108354864B (en) | Preparation method of emulsion with whitening and moisturizing effects | |
| KR20090103992A (en) | Use of gamma-amino butyric acid as a depigmenting agent | |
| CN116509750A (en) | Composite fish collagen mask liquid and preparation method thereof | |
| EP2868313B1 (en) | Combination of vitamin C and hyaluronic acid for the treatment of skin ageing effects | |
| CN115778880A (en) | Liposome, preparation method and application thereof | |
| CN115813774A (en) | Water-oil double-layer refined composition with whitening effect and preparation method and application thereof | |
| CN115531226A (en) | Preparation method and whitening application of glycyrrhizic acid-licochalcone A micelle emulsion | |
| FR2948877A1 (en) | Topical composition, useful e.g. to protect and regenerate the skin, comprises an active complex comprising combination of plant extracts containing Alaria esculenta algae extract and Crambe maritima extract | |
| CN109602666B (en) | Whitening composition containing lime fruit extract | |
| CN109620770A (en) | A kind of whitening highlights composition and preparation method thereof | |
| KR102598627B1 (en) | Manufacturing method of astaxanthin solution with improved stability and cosmetic composition comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200728 |
|
| RJ01 | Rejection of invention patent application after publication |